FDA Approves Foundayo (orforglipron): First Oral GLP-1 Pill for Weight Loss
<cite index="34-14,34-15">Foundayo (orforglipron) is FDA-approved for adults with obesity or some adults with overweight who have weight-related medical problems, and is a once-daily oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake.</cite> The approval marks a significant shift in weight-loss therapy, offering an alternative to injectable GLP-1 medications.
Drug Profile & Approval
FDA has approved Foundayo (vepdegestrant) in May 2026 for treatment of obesity. Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. The once-daily formulation eliminates the need for frequent injections.
Clinical Use & Accessibility
If approved, this would provide an alternative to the current bi-weekly intravenous dosage regimen, allowing patients and caregivers to administer the medication at home for both initial and maintenance therapy. In addition to chronic weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.
Safety Considerations
Foundayo may cause tumors in the thyroid, including thyroid cancer, and common side effects include nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss.